drugset / Trial / NCT00199368
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
Timeline
- Start
- 2004-10
- Primary completion
- 2007-03
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Istradefylline | Small molecule | 20 mg | Oral |
| Subject | Istradefylline | Small molecule | 40 mg | Oral |